Xingqi Pharmaceutical

Shenyang Xingqi Pharmaceutical Co., Ltd. is a national high-tech enterprise specializing in the research, production, and sales of ophthalmic drugs. On December 8, 2016, the company was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, with the stock abbreviation: Xingqi Pharmaceutical, and the stock code: 300573. The company adheres to the mission of "Managing health, creating brightness"; its vision is to "Become an ophthalmic drug research and manufacturing enterprise with global competitiveness"; practicing the values of "Responsibility, precision, persistence, innovation, and dedication," actively contributing to the human eye health industry. Currently, the company's products include ophthalmic anti-infectives, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and ocular lubricants, dry eye treatment drugs, nutritional and corneal repair drugs, mydriatics and cycloplegics, non-steroidal ophthalmic anti-inflammatory drugs, miotics and anti-glaucoma medications, intraoperative ocular irrigation solutions, etc., covering more than ten subcategories of ophthalmic drugs, providing high-quality products for the field of ophthalmic disease treatment. Innovation is the driving force behind the company’s development. The company owns the Liaoning Provincial Enterprise Technology Center, the Liaoning Provincial Ophthalmic Drug Professional Technology Innovation Center, the Liaoning Provincial Children and Adolescent Myopia Prevention and Control Engineering Research Center, and the Liaoning Industrial Technology Research Institute Xingqi Pharmaceutical Joint Innovation Center. In the field of ophthalmic drug research and development, it has built research platforms such as conventional ophthalmic formulations, in-situ gels, sustained-release formulations, ophthalmic GLP laboratories, and pharmaceutical packaging materials, demonstrating comprehensive R&D and innovation capabilities in ophthalmic drugs. In October 2020, the company’s Quality Testing Center received CNAS accreditation from the China National Accreditation Service for Conformity Assessment, marking that the "Center" has the capability to conduct experimental testing according to recognized standards.Quality originates from design, and superior products come from the continuous pursuit of details. In 2014, the company’s Qipanshan factory was fully commissioned. The factory was designed in reference to U.S. FDA cGMP and EU GMP standards, constructed through close cooperation by internationally top-tier design teams, equipment suppliers, and engineering companies. It has multiple production lines that meet China’s GMP standards, including extraction production lines, single-dose eye drop production lines, multi-dose eye drop production lines, ophthalmic gel production lines, ophthalmic solution production lines, and ophthalmic inner packaging material production lines. Based on its ophthalmic drug R&D and manufacturing business, the company, guided by market demand, closely collaborates with domestic and international scientific research institutions, medical institutions, and ophthalmology experts to promote the transformation of scientific research achievements; through professional academic promotion, it leads market sales. Through a well-established marketing system, it establishes cooperative relationships with distributors at all levels, with a product sales network covering provincial, municipal, and county-level medical institutions across China.